Passage Bio, Inc. (PASG)
Oxford Ledge is still expanding full research coverage of PASG. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical-stage gene therapy company developing PBFT02 to treat neurodegenerative diseases by restoring progranulin levels in the brain.
SEC filings
- 8-K Entry into material agreement; Termination of material agreement; 3.02; 5.01; Departure/election of directors or officers; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-24
- 8-K Termination of material agreement 2026-05-27
- 8-K Shareholder vote results 2026-05-26
- 10-Q Quarterly financial report (unaudited) 2026-05-12
- 8-K Costs for exit or disposal activities 2026-04-28
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for PASG. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open PASG in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.